List of compounds screened for their ability to improve tactile hypersensitivity in Nf1P1 larvae
| Process targeted | Compound | Mechanism of action | Source |
|---|---|---|---|
| Ras/MAPK signalling | Lovastatin | HMG CoA-reductase inhibitor | Generon |
| Fluvastatin sodium | Generon | ||
| Simvastatin | Fluorochem | ||
| Atorvastatin calcium | Generon | ||
| Binimetinib | MEK inhibitor | Generon | |
| U0126 | Cambridge Bioscience | ||
| GDC-0973 (Cobimetinib) | Generon | ||
| PD 0325901 | Merck | ||
| Salirasib | Ras inhibitor | Generon | |
| GNE 3511 | DLK inhibitor | Generon | |
| Palbociclib HCl | CDK4/6 inhibitor | Generon | |
| Vorinostat | HDAC inhibitor | Generon | |
| Belinostat | Generon | ||
| Trichostatin A | Cambridge Bioscience | ||
| BAY293 | Ras/SOS1 interaction inhibitor | Generon | |
| Ion channel function | ML 6733 | K2P activator | Generon |
| BMS-204352 | BKCa channel activator | Cambridge Bioscience/Scientific Laboratory Supplies | |
| BAY K 8644 | L-type Cav channel activator | Stratech Scientific Ltd | |
| Lamotrigine | Sodium channel blocker | Fisher Scientific UK Ltd | |
| SKA 31 | SK channel activator | Bio-Techne |
Compounds were selected based on either their ability to inhibit Ras/MAPK activity or to modulate ion channel function, mostly with the expectation of reducing neuronal excitability. As part of the “Ras/MAPK” targeting group, inhibitors of histone deacetylase (HDAC) and CDK4/6 were included since they have been demonstrated to improve viability in Drosophila models of other RASopathies (Das et al., 2021).